Redefining druggable targets with artificial intelligence

Karen Akinsanya¹, Mohammed AlQuraishi², Ann Boija³, John Chodera⁴, Anna Cichońska⁵, Marzyeh Ghassemi⁶, Martha Head⁷, Wengong Jin⁸, Warren A Kibbe⁹, Nevan Krogan¹⁰, Michael V LeVine¹¹, John Moult¹², Lynda Stuart¹³, Georgia Tourassi¹⁴, James Zou¹⁵, Regina Barzilay¹⁶, Olivier Elemento¹⁷

Affiliations

¹ Schrödinger, New York, NY, USA.
² Department of Systems Biology, Columbia University, New York, NY, USA.
³ Dewpoint Therapeutics, Boston, MA, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Harmonic Discovery, New York, NY, USA.
⁶ Massachusetts Institute of Technology, Cambridge, MA, USA.
⁷ Amgen, Cambridge, MA, USA.
⁸ Khoury College of Computer Science, Northeastern University, Boston, MA, USA.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ University of California San Francisco, San Francisco, CA, USA.
¹¹ Genesis Therapeutics, Burlington, CA, USA.
¹² University of Maryland, College Park, MD, USA.
¹³ Institute for Protein Design, Seattle, WA, USA.
¹⁴ Oak Ridge National Laboratory, Oak Ridge, TN, USA.
¹⁵ Stanford University, Stanford, CA, USA.
¹⁶ Massachusetts Institute of Technology, Cambridge, MA, USA. regina@csail.mit.edu.
¹⁷ Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. ole2001@med.cornell.edu.

PMID: 40830262
DOI: 10.1038/s41587-025-02770-1

Redefining druggable targets with artificial intelligence

Karen Akinsanya et al. Nat Biotechnol. 2025 Sep.

. 2025 Sep;43(9):1416-1418.

doi: 10.1038/s41587-025-02770-1.

Authors

Affiliations

¹ Schrödinger, New York, NY, USA.
² Department of Systems Biology, Columbia University, New York, NY, USA.
³ Dewpoint Therapeutics, Boston, MA, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Harmonic Discovery, New York, NY, USA.
⁶ Massachusetts Institute of Technology, Cambridge, MA, USA.
⁷ Amgen, Cambridge, MA, USA.
⁸ Khoury College of Computer Science, Northeastern University, Boston, MA, USA.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ University of California San Francisco, San Francisco, CA, USA.
¹¹ Genesis Therapeutics, Burlington, CA, USA.
¹² University of Maryland, College Park, MD, USA.
¹³ Institute for Protein Design, Seattle, WA, USA.
¹⁴ Oak Ridge National Laboratory, Oak Ridge, TN, USA.
¹⁵ Stanford University, Stanford, CA, USA.
¹⁶ Massachusetts Institute of Technology, Cambridge, MA, USA. regina@csail.mit.edu.
¹⁷ Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. ole2001@med.cornell.edu.

PMID: 40830262
DOI: 10.1038/s41587-025-02770-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: A.B. is an employee and shareholder of Dewpoint Therapeutics and holds multiple patents related to the work discussed in this Comment. A.C. is an employee and stock option holder at Harmonic Discovery. K.A. is stock holder in Schrodinger and Nautilus Biotechnology. M.A. is a member of the scientific advisory boards of Cyrus Biotechnology, Deep Forest Sciences, Nabla Bio, Oracle Therapeutics, and Achira. O.E. is co-founder and stock holder in Volastra Therapeutics, holds stock in Freenome, serves as a member of the scientific advisory board (SAB) and holds stock options in Owkin, Harmonic Discovery, and Exai, is an SAB member for Canary Biosciences, and is receiving or has received funding from Eli Lilly, J&J/Janssen, Sanofi, AstraZeneca, and Volastra. J.C., M.G., M.H., W.J., W.A.K., N.K., M.V.L., J.M., L.S., G.T., J.Z., and R.B. declare no competing interests.

References

1. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013). - PubMed - PMC
1. Abramson, J. et al. Nature 630, 493–500 (2024). - PubMed - PMC
1. Ahdritz, G. et al. Nat. Methods 21, 1514–1524 (2024). - PubMed - PMC
1. Shaw, D. E. et al. Commun. ACM 51, 91–97 (2008).
1. Boija, A. et al. Cell 175, 1842–1855 (2018). - PubMed

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Redefining druggable targets with artificial intelligence

Affiliations

Redefining druggable targets with artificial intelligence

Authors

Affiliations

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources